GlassScriptPhysician profile
Amy Makemson
NPI 1790768976
$12,906.12
in general payments reported to CMS, 2019-2025
64 companies · $2,073 in 2025
The $2,073 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,659 · 2020: $1,556 · 2021: $1,886 · 2022: $1,906 · 2023: $2,096 · 2024: $1,731 · 2025: $2,073.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,805 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,804.63 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,855.33 | 2019-2025 | |
| Novo Nordisk INC | $1,639.94 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,179.17 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $982.31 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Allergan, INC. | $627.33 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $541.91 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $437.57 | 2019-2024 | Trintellix |
| Astellas Pharma US INC | $392.79 | 2020-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $359.20 | 2019-2025 | |
| Glaxosmithkline, LLC. | $322.48 | 2019-2025 | Trelegy Ellipta |
| Axsome Therapeutics, INC. | $273.14 | 2023-2025 | Sunosi, Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $245.81 | 2019-2024 | Tradjenta, Synjardy, Jardiance |
| Abbott Laboratories | $219.58 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2, Eterna |
| Eisai INC. | $219.13 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $216.98 | 2022 |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Makemson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.